Prevention & lipidsTrial design
Rationale and design of the Corrie Lipids Program: Impact of a digital health–enabled implementation initiative to improve lipid management
- prospective, multicenter, implementation science study
- No randomization or control group
- RE-AIM framework
- Qualitative interviews with patients and clinicians
Study context
- Population
- Adult patients with uncontrolled low-density lipoprotein cholesterol (LDL-C) and at high risk for atherosclerotic cardiovascular disease (ASCVD), defined as known or subclinical ASCVD diagnosed by imaging, familial hypercholesterolemia or LDL-C ≥190 mg/dL, diabetes mellitus, individuals who meet criteria for lipid-lowering therapy based on ASCVD risk assessment in the most up-to-date guidelines, or statin-intoleranceestimated enrollment, 124 patients enrolled as of March 1, 2026
- Participants
- 1,000 patients
- Primary endpoint
- Proportion of high-risk patients achieving guideline-directed LDL-C goals
- Follow-up
- 6 and 12 months
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Study conduct · as of March 1, 2026
- Patients enrolled
- 124
- Currently enrolling; initiated in June 2025 with estimated completion of follow-up by early 2027
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Rationale and design of the Corrie Lipids Program: Impact of a digital health–enabled implementation initiative to improve lipid management. Am Heart J. Published 2 April 2026. doi:10.1016/j.ahj.2026.107440
Summarised from the published abstract; every number is checked against it